Oxford Biomedica マネジメント

マネジメント基準チェック /24

Oxford Biomedicaの CEO はFrank Mathiasで、 Mar2023年に任命され、の在任期間は 1.67年です。の年間総報酬は£ 520.00Kで、 88.1%給与と11.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.019%を直接所有しており、その価値は£ 84.89K 。経営陣と取締役会の平均在任期間はそれぞれ1.2年と3.7年です。

主要情報

Frank Mathias

最高経営責任者

UK£520.0k

報酬総額

CEO給与比率	88.1%
CEO在任期間	1.7yrs
CEOの所有権	0.02%
経営陣の平均在職期間	1.2yrs
取締役会の平均在任期間	3.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Oxford Biomedica の収益と比較して、Frank Mathias の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-UK£142m
Mar 31 2024	n/a	n/a	-UK£150m
Dec 31 2023	UK£520k	UK£458k	-UK£157m

報酬と市場: Frankの総報酬 ($USD 652.67K ) は、 UK市場 ($USD 989.04K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Frankの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Frank Mathias (62 yo)

1.7yrs

在職期間

UK£520,000

報酬

Dr. Frank Mathias is Chief Executive Officer and Director of Oxford Biomedica plc from March 27, 2023. Dr. Mathias was the Chief Executive Officer of Rentschler Biopharma SE from April 2016 until March 202...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Frank Mathias	CEO & Director	1.7yrs	UK£520.00k	0.019% £ 84.9k
Lucinda Crabtree	CFO & Director	less than a year	データなし	データなし
Thierry Cournez	Chief Operating Officer	1.1yrs	データなし	データなし
Sophia Bolhassan	Head of Investor Relations	no data	データなし	データなし
Natalie Walter	General Counsel & Company Secretary	5.5yrs	データなし	データなし
Lisa Doman	Chief People Officer	2.6yrs	データなし	データなし
Kyriacos Mitrophanous	Chief Innovation Officer	less than a year	データなし	データなし
Kati Hudson	Head of Intellectual Property and Contracts	no data	データなし	データなし
Sebastien Ribault	Chief Business Officer	2yrs	データなし	データなし
Mark Caswell	Site Head of UK Operations	1.3yrs	データなし	データなし
Stephanie Colloud	Site Head & GM of France Operations	less than a year	データなし	データなし
Sabine Sydow	Chief of Staff	less than a year	データなし	データなし

1.2yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: OXBLの経営陣は経験豊富とはみなされません ( 1.2年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Frank Mathias	CEO & Director	1.7yrs	UK£520.00k	0.019% £ 84.9k
Lucinda Crabtree	CFO & Director	less than a year	データなし	データなし
Frederic Doliveux	Non-Executive Chair	4.4yrs	UK£225.00k	0.35% £ 1.6m
William Langston	Member of Scientific Advisory Board	no data	データなし	データなし
Peter Stern	Member of Scientific Advisory Board	no data	データなし	データなし
Krystof Bankiewicz	Member of Scientific Advisory Board	no data	データなし	データなし
Leone Patterson	Independent Non-Executive Director	1.5yrs	UK£87.00k	0.012% £ 52.8k
Heather Preston	Independent Non-Executive Director	6.7yrs	UK£140.00k	0.017% £ 77.7k
Dame Davies	Senior Independent Director	3.7yrs	UK£73.00k	0.00095% £ 4.2k
Stuart Henderson	Independent Vice Chair	8.4yrs	UK£85.00k	0.010% £ 46.1k
Robert Ghenchev	Non-Executive Director	5.4yrs	データなし	データなし
Namrata Patel	Independent Non-Executive Director	2.6yrs	UK£65.00k	0.0087% £ 38.9k

3.7yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: OXBLの取締役会は経験豊富であると考えられます ( 3.7年の平均在任期間)。

Oxford Biomedica マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc Appoints Lucinda (Lucy) Crabtree as Board Member

Oxford Biomedica plc Announces Appointment of Laurence Espinasse as Non-Executive Director

Oxford Biomedica plc Announces CFO Changes, Effective from September 2, 2024

Oxford Biomedica plc, Annual General Meeting, Jun 24, 2024

Oxford Biomedica plc Announces Board Changes

Recent updates

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc Provides Earnings Guidance for the Full Year 2024

Oxford Biomedica plc Appoints Lucinda (Lucy) Crabtree as Board Member

Oxford Biomedica plc Provides Earnings Guidance for the First Half of 2024 and Reiterates for the Full Year 2024

Oxford Biomedica plc Announces Appointment of Laurence Espinasse as Non-Executive Director

Oxford Biomedica plc Announces CFO Changes, Effective from September 2, 2024

Oxford Biomedica plc, Annual General Meeting, Jun 24, 2024

Oxford Biomedica plc Reiterates Earnings Guidance for the Year 2024

Full year 2023 earnings released: UK£1.63 loss per share (vs UK£0.41 loss in FY 2022)

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc to Report Fiscal Year 2023 Results on Apr 29, 2024

New minor risk - Shareholder dilution

Oxford Biomedica plc (LSE:OXB) completed the acquisition of additional 3.2% stake in ABL EUROPE S.A.S. from TSGH.

Oxford Biomedica plc (LSE:OXB) completed the acquisition of additional 3.2% stake in ABL EUROPE S.A.S. from TSGH.

Oxford Biomedica plc Provides Business Update

Oxford Biomedica plc (LSE:OXB) entered into a sale and purchase agreement to acquire ABL EUROPE S.A.S. from TSGH for €15 million.

New minor risk - Share price stability

Non-Executive Chair recently bought UK£99k worth of stock

First half 2023 earnings released: UK£0.50 loss per share (vs UK£0.27 loss in 1H 2022)

Oxford Biomedica Talks to Buy ABL Europe

Oxford Biomedica Talks to Buy ABL Europe

Oxford Biomedica plc Provides Revenue Guidance for the Year 2023 and 2024

Oxford Biomedica plc to Report First Half, 2023 Results on Sep 20, 2023

Oxford Biomedica plc Launches TetraVectaTM - the Next Generation Lendediviral Vector System

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Full year 2022 earnings released: UK£0.41 loss per share (vs UK£0.23 profit in FY 2021)

High number of new directors

Oxford Biomedica plc Announces Siyamak Rasty Will Not Be Standing for Re-Election

Oxford Biomedica Appoints Frank Mathias as Board Director

High number of new directors

Kadans Science Partner B.V. agreed to acquire Windrush Court facility from Oxford Biomedica plc (LSE:OXB) for £60 million.

First half 2022 earnings released: EPS: UK£0 (vs UK£0.22 in 1H 2021)

Oxford Biomedica plc Provides Earnings Guidance for the Second Half of 2022

Oxford Biomedica plc to Report First Half, 2022 Results on Sep 15, 2022

Oxford Biomedica plc(LSE:OXB) dropped from FTSE 350 Index (GBP)

Investor sentiment deteriorated over the past week

Oxford Biomedica Notes Announcement That FDA Has Lifted Clinical Hold on Homology Medicines' Phenix Trial

John Dawson Has Steps Down from the Oxford Biomedica Plc's Board of Directors

Full year 2021 earnings released: EPS: UK£0.23 (vs UK£0.078 loss in FY 2020)

High number of new directors

Interim CEO & Chairman recently bought UK£343k worth of stock

Full year 2021 earnings released: EPS: UK£0.23 (vs UK£0.078 loss in FY 2020)

Oxford Biomedica plc Provides Revenue Guidance for the Year 2022

Oxford Biomedica plc Announces the Appointment of Namrata P Patel as Independent Non-Executive Director

Oxford Biomedica plc to Report Fiscal Year 2021 Results on Apr 20, 2022

Investor sentiment deteriorated over the past week

Oxford Biomedica plc, Annual General Meeting, Mar 08, 2022

Investor sentiment deteriorated over the past week

Oxford Biomedica plc announced that it expects to receive £50.000001 million in funding

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.087 loss in 1H 2020)

Non-Executive Director Andrew John Heath has left the company

Full year 2020 earnings released: UK£0.078 loss per share (vs UK£0.22 loss in FY 2019)

Oxford Biomedica plc Provides Earning Guidance for the Year 2021

Oxford Biomedica plc to Report Fiscal Year 2020 Results on Apr 15, 2021

Non-Executive Director has left the company

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc(LSE:OXB) dropped from FTSE All-Small Index (GBP)

New 90-day high: UK£8.83

Independent Non-Executive Director recently sold UK£385k worth of stock

Oxford Biomedica plc Appoints Sam Rasty as Non-Executive Director

Oxford Biomedica plc and PhoreMost Enters Gene Therapy Collaboration

Oxford Biomedica plc Notes Axovant’S Positive Six-Month Follow-Up from Second Cohort of Sunrise- PD Phase 2 Trial of Axo-Lenti-Pd

Papyrus Therapeutics Inc. Signs Research Collaboration With Oxford Biomedica plc

Oxford Biomedica plc to Report First Half, 2020 Results on Sep 17, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

マネジメント基準チェック /24